The prevalence of prenatal cannabis use has nearly doubled in the United States. Cannabinoid 2 receptors are predominately expressed in cells of the human immune system, and delta-9 tetrahydrocannabinol (THC), the primary active component of cannabis, has been shown to suppress immune responses. Despite these findings, there is very little evidence on the impact of cannabis use on maternal immune system. Here, we evaluate the association between urine-verified cannabis use and the levels of T helper cytokines in the maternal circulation.
Methods:
This was an ancillary study of a prospective cohort of pregnant women who participated in the Michigan Archive for Research on Child Health study. Pregnant women (age ≥18 years) were recruited from 22 prenatal clinics in Michigan and matched on age, race, and tobacco smoking (n = 144). The urinary metabolite of delta-9 THC, 11-nor-9-carboxy-delta-9-THC (THC-COOH), was used to define cannabis use status. A bead-based assay was used for the simultaneous detection of maternal cytokines associated with cannabis use and pregnancy outcomes in previous studies.
Results:
Repeated-measures linear mixed models indicated that urine-verified cannabis use was associated with the suppression of maternal pro-inflammatory cytokines including interferon gamma (β = −0.5; 95% confidence interval [CI] = −0.8, −0.1) and interleukin (IL)-12 (β = −0.3; 95% CI = −0.6, −0.05), as well as the anti-inflammatory IL-4 (β = −0.7; 95% CI = −1.3, −0.2) and IL-10 (β = −0.4; 95% CI = −0.7, −0.03). Similar results were observed when heavy cannabis use was defined using the top tertile of urinary THC-COOH at each trimester.
Conclusions:
Urine-verified cannabis use was associated with the suppression of pro- and anti-inflammatory T helper cytokines in a cohort of pregnant women, suggesting that cannabis use can lead to modest dysregulation of the maternal immune system. Additional studies are needed to investigate the role of maternal immune responses in explaining birth outcomes linked to cannabis use.
AlshaarawyO, VanderzielA. Trends and characteristics of prenatal cannabis use in the U.S., 2002–2019. Am J Prev Med, 2022; 63(5):846–851.
2.
GrigsbyTJ, AssoumouB, KoningSM, et al.Cannabis use among pregnant and nonpregnant women of childbearing age: findings from the 2021–2023 national survey of drug use and health. Am J Prev Med, 2025; 69(4):107967.
3.
ElSohlyMA, ChandraS, RadwanM, et al.A comprehensive review of cannabis potency in the United States in the last decade. Biol Psychiatry Cogn Neurosci Neuroimaging, 2021; 6(6):603–606.
4.
MetzTD, StickrathEH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol, 2015; 213(6):761–778.
5.
WegmannTG, LinH, GuilbertL, et al.Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today, 1993; 14(7):353–356.
6.
HussainT, MurtazaG, KalhoroDH, et al.Understanding the immune system in fetal protection and maternal infections during pregnancy. J Immunol Res, 2022; 2022:7567708.
7.
NegishiY, TakahashiH, KuwabaraY, et al.Innate immune cells in reproduction. J Obstet Gynaecol Res, 2018; 44(11):2025–2036.
8.
PattersonPH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res, 2009; 204(2):313–321.
9.
CappellettiM, Della BellaS, FerrazziE, et al.Inflammation and preterm birth. J Leukoc Biol, 2016; 99(1):67–78.
10.
PertweeRG, HowlettAC, AboodME, et al.International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev, 2010; 62(4):588–631.
11.
MackieK. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol, 2006; 46:101–122.
12.
NagarkattiP, PandeyR, RiederSA, et al.Cannabinoids as novel anti-inflammatory drugs. Future Med Chem, 2009; 1(7):1333–1349.
13.
PertweeRG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol, 2008; 153(2):199–215.
14.
YuanM, KiertscherSM, ChengQ, et al.Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol, 2002; 133(1–2):124–131.
15.
KarmausPW, ChenW, CrawfordR, et al.Delta9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2. Toxicol Sci, 2013; 131(2):419–433.
16.
KarmausPW, ChenW, KaplanBL, et al.Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events. J Neuroimmune Pharmacol, 2012; 7(4):843–855.
17.
MetzTD, AllshouseAA, McMillinGA, et al.Cannabis exposure and adverse pregnancy outcomes related to placental function. JAMA, 2023; 330(22):2191–2199.
18.
Young-WolffKC, AdamsSR, AlexeeffSE, et al.Prenatal cannabis use and maternal pregnancy outcomes. JAMA Intern Med, 2024; 184(9):1083–1093.
19.
SundramS. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol, 2006; 21(4):245–254.
20.
DukoB, DachewBA, PereiraG, et al.The effect of prenatal cannabis exposure on offspring preterm birth: a cumulative meta-analysis. Addiction, 2023; 118(4):607–619.
21.
RompalaG, NomuraY, HurdYL. Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring. Proc Natl Acad Sci U S A, 2021; 118(47):e2106115118.
22.
AshfordK, Fallin-BennettA, McCubbinA, et al.Associations of first trimester co-use of tobacco and cannabis with prenatal immune response and psychosocial well-being. Neurotoxicol Teratol, 2019; 73:42–48.
23.
Young-WolffKC, SarovarV, TuckerL-Y, et al.Validity of self-reported cannabis use among pregnant females in Northern California. J Addict Med, 2020; 14(4):287–292.
24.
AlshaarawyO, AnthonyJC. Cannabis use among women of reproductive age in the United States: 2002–2017. Addict Behav, 2019; 99:106082.
25.
VanderzielA, AnthonyJC, BarondessD, et al.Nausea and vomiting of pregnancy and prenatal cannabis use in a Michigan sample. Am J Obstet Gynecol MFM, 2023; 5(12):101171.
26.
VanderzielA, AnthonyJC, BarondessD, et al.Estimating the effects of prenatal cannabis exposure on birth outcomes. Am J Addict, 2024; 34(1):21–29.
27.
CookDE. CCMATCH: Stata module to match cases and controls using specified variables. Statistical Software Components. Boston College Department of Economics; 2011.
28.
HuestisMA. Human cannabinoid pharmacokinetics. Chem Biodivers, 2007; 4(8):1770–1804.
29.
ScheidweilerKB, BarnesAJ. Quantification of eight cannabinoids including cannabidiol in human urine via liquid chromatography tandem mass spectrometry. In: LangmanLJ, SnozekCLH, editors. LC-MS in Drug Analysis: Methods and Protocols. Springer New York: New York, NY; 2019. pp. 11–22.
PerriconeR, De CarolisC, GiacomelliR, et al.GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. Am J Reprod Immunol, 2003; 50(3):232–237.
32.
RobertsonSA. GM-CSF regulation of embryo development and pregnancy. Cytokine Growth Factor Rev, 2007; 18(3–4):287–298.
33.
HayashiM, HamadaY, OhkuraT. Elevation of granulocyte-macrophage colony-stimulating factor in the placenta and blood in preeclampsia. Am J Obstet Gynecol, 2004; 190(2):456–461.
34.
CurryAE, ThorsenP, DrewsC, et al.First-trimester maternal plasma cytokine levels, pre-pregnancy body mass index, and spontaneous preterm delivery. Acta Obstet Gynecol Scand, 2009; 88(3):332–342.
35.
ZgairA, LeeJB, WongJCM, et al.Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep, 2017; 7(1):14542.
36.
SzaboSJ, SullivanBM, PengSL, et al.Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol, 2003; 21:713–758.
37.
CurryAE, VogelI, DrewsC, et al.Mid-pregnancy maternal plasma levels of interleukin 2, 6, and 12, tumor necrosis factor-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor and spontaneous preterm delivery. Acta Obstet Gynecol Scand, 2007; 86(9):1103–1110.
38.
MurphySP, TayadeC, AshkarAA, et al.Interferon gamma in successful pregnancies. Biol Reprod, 2009; 80(5):848–859.
39.
KleinTW, NewtonCA, NakachiN, et al.Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol, 2000; 164(12):6461–6466.
40.
Lopez-CastejonG, BroughD. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev, 2011; 22(4):189–195.
41.
LöbS, AmannN, KuhnC, et al.Interleukin-1 beta is significantly upregulated in the decidua of spontaneous and recurrent miscarriage placentas. J Reprod Immunol, 2021; 144:103283.
42.
AmashA, HolcbergG, SapirO, et al.Placental secretion of interleukin-1 and interleukin-1 receptor antagonist in preeclampsia: effect of magnesium sulfate. J Interferon Cytokine Res, 2012; 32(9):432–441.
43.
SuryavanshiSV, KovalchukI, KovalchukO. Cannabinoids as key regulators of Inflammasome signaling: a current perspective. Front Immunol, 2020; 11:613613.
44.
RossSH, CantrellDA. Signaling and function of Interleukin-2 in T lymphocytes. Annu Rev Immunol, 2018; 36(1):411–433.
45.
CunninghamMW, AmaralLM, CampbellNE, et al.Investigation of interleukin-2-mediated changes in blood pressure, fetal growth restriction, and innate immune activation in normal pregnant rats and in a preclinical rat model of preeclampsia. Biol Sex Differ, 2021; 12(1):4.
46.
MallmannP, MallmannR, KrebsD. Determination of tumor necrosis factor alpha (TNFα) and Interleukin 2 (IL2) in women with idiopathic recurrent miscarriage. Arch Gynecol Obstet, 1991; 249(2):73–78.
47.
KawakamiY, KleinTW, NewtonC, et al.Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J Immunopharmacol, 1988; 10(4):485–488.
48.
SmileyST, GrusbyMJ. Interleukin 4. In: DelvesPJ, editor. Encyclopedia of Immunology (Second Edition).. Elsevier: Oxford; 1998. pp. 1451–1453.
49.
ChatterjeeP, KoprivaSE, ChiassonVL, et al.Interleukin-4 deficiency induces mild preeclampsia in mice. J Hypertens, 2013; 31(7):1414–1423; discussion 1423.
50.
ChatterjeeP, ChiassonVL, BoundsKR, et al.Regulation of the anti-inflammatory cytokines Interleukin-4 and Interleukin-10 during pregnancy. Front Immunol, 2014; 5:253.
51.
CroxfordJL, YamamuraT. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol, 2005; 166(1–2):3–18.
52.
TanakaT, NarazakiM, KishimotoT. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014; 6(10):a016295.
53.
LockwoodCJ, YenC-F, BasarM, et al.Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. Am J Pathol, 2008; 172(6):1571–1579.
54.
KeenL2nd, PereiraD, LatimerW. Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans. Drug Alcohol Depend, 2014; 140:156–160.
55.
AlshaarawyO, SidneyS, AuerR, et al.Cannabis use and markers of systemic inflammation The Coronary Artery Risk Development in Young Adults Study. Am J Med, 2019.
56.
ChenD, TangT-X, DengH, et al.Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. Front Immunol, 2021; 12:747324.
57.
VilsmaierT, AmannN, LöbS, et al.The decidual expression of interleukin-7 is upregulated in early pregnancy loss. Am J Reprod Immunol, 2021; 86(3):e13437.
58.
KozelaE, JuknatA, KaushanskyN, et al.Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol, 2013; 8(5):1265–1276.
59.
BrennanK, ZhengJ. Interleukin 8. In: EnnaSJ, BylundDB, editors. xPharm: The Comprehensive Pharmacology Reference. Elsevier: New York; 2007. pp. 1–4.
60.
KrasnyiAM, SadekovaAA, VtorushinaVV, et al.Extracellular DNA levels and cytokine profiles in preterm birth: A cohort study. Arch Gynecol Obstet, 2022; 306(5):1495–1502.
61.
VilotićA, Nacka-AleksićM, PirkovićA, et al.IL-6 and IL-8: An overview of their roles in healthy and pathological pregnancies. Int J Mol Sci, 2022; 23(23):14574.
62.
SuryavanshiSV, ZaiachukM, PryimakN, et al.Cannabinoids alleviate the LPS-induced cytokine storm via attenuating NLRP3 inflammasome signaling and TYK2-mediated STAT3 signaling pathways in vitro. Cells, 2022; 11(9):1391.
63.
BayazitH, SelekS, KarababaIF, et al.Evaluation of oxidant/antioxidant status and cytokine levels in patients with cannabis use disorder. Clin Psychopharmacol Neurosci, 2017; 15(3):237–242.
64.
IyerSS, ChengG. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol, 2012; 32(1):23–63.
65.
NathMC, CubroH, McCormickDJ, et al.Preeclamptic women have decreased circulating IL-10 (interleukin-10) values at the time of preeclampsia diagnosis. Hypertension, 2020; 76(6):1817–1827.
66.
LiuJ, CaoS, KimS, et al.Interleukin-12: An update on its immunological activities, signaling and regulation of gene expression. Curr Immunol Rev, 2005; 1(2):119–137.
67.
SakaiM, TsudaH, TanebeK, et al.Interleukin-12 secretion by peripheral blood mononuclear cells is decreased in normal pregnant subjects and increased in preeclamptic patients. Am J Reprod Immunol, 2002; 47(2):91–97.
68.
DanielY, KupfermincMJ, BaramA, et al.Plasma interleukin-12 is elevated in patients with preeclampsia. Am J Reprod Immunol, 1998; 39(6):376–380.
69.
ArababadiMK, AminzadehF, HassanshahiG, et al.Cytokines in preterm delivery. Lab Med, 2012; 43(4):27–30.
70.
KatonaS, KaminskiE, SandersH, et al.Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol, 2005; 140(3):580–585.
71.
JunttilaIS. Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol, 2018; 9:888.
72.
ThürmannL, HerberthG, Rolle-KampczykU, et al.Elevated gestational IL-13 during fetal development is associated with hyperactivity and inattention in eight-year-old children. Front Immunol, 2019; 10:1658.
73.
RothersJ, SternDA, LohmanIC, et al.Maternal cytokine profiles during pregnancy predict asthma in children of mothers without asthma. Am J Respir Cell Mol Biol, 2018; 59(5):592–600.
74.
HaidarZ, TraboulsiH, EidelmanDH, et al.Differential inflammatory profile in the lungs of mice exposed to cannabis smoke with varying THC:CBD ratio. Arch Toxicol, 2023; 97(7):1963–1978.
75.
NadiaM, MatthewFF, JoshuaJCM, et al.Cannabis smoke suppresses antiviral immune responses to influenza A in mice. ERJ Open Res, 2023; 9(6):219–2023.
76.
JangD-I, LeeA-H, ShinH-Y, et al.The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci, 2021; 22(5):2719.
77.
LauSY, GuildS-J, BarrettCJ, et al.Tumor necrosis factor-alpha, Interleukin-6, and Interleukin-10 levels are altered in preeclampsia: A systematic review and meta-analysis. Am J Reprod Immunol, 2013; 70(5):412–427.
78.
MohammedA, AlghetaaH, SultanM, et al.Administration of Δ9‐tetrahydrocannabinol (THC) post-Staphylococcal enterotoxin B exposure protects mice from acute respiratory distress syndrome and toxicity. Front Pharmacol, 2020; 11:893.
79.
ManuzakJA, GottTM, KirkwoodJS, et al.Heavy cannabis use associated with reduction in activated and inflammatory immune cell frequencies in antiretroviral therapy-treated human immunodeficiency virus-infected individuals. Clin Infect Dis, 2018; 66(12):1872–1882.
80.
KeenL2nd, TurnerAD. Differential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults. J Behav Med, 2015; 38(3):527–534.
81.
KoJY, FarrSL, TongVT, et al.Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol, 2015; 213(2):201.e1–e10.
CorsiDJ, WalshL, WeissD, et al.Association between self-reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes. JAMA, 2019; 322(2):145–152.
84.
CorsiDJ, DonelleJ, SuchaE, et al.Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat Med, 2020; 26(10):1536–1540.
85.
Abu-RayaB, MichalskiC, SadaranganiM, et al.Maternal immunological adaptation during normal pregnancy. Front Immunol, 2020; 11:575197.
86.
LuoZ, FittingS, RobinsonC, et al.Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes, macrophage infiltration, and increases β-amyloid protein production in the brain. EBioMedicine, 2021; 74:103701.
87.
KnappAA, LeeDC, BorodovskyJT, et al.Emerging trends in cannabis administration among adolescent cannabis users. J Adolesc Health, 2019; 64(4):487–493.
88.
WeiB, AlwisKU, LiZ, et al.Urinary concentrations of PAH and VOC metabolites in marijuana users. Environ Int, 2016; 88:1–8.
